Yupelri (revefenacin) inhalation solution, from Mylan/Viatris in partnership with Theravance Biopharma, is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD).
Revefenacin is a long-acting muscarinic antagonist (LAMA) that blocks acetylcholine receptors in the airway smooth muscle, causing bronchodilation and helping to reduce COPD symptoms such as breathlessness.
Yupelri may be imported in the patient’s name only, by patients or government hospitals. The following documentation is required:
The order is confirmed only after receipt and verification of a valid prescription.
Yupelri is not commercially marketed in India. It can be legally accessed through the Named Patient Program (NPP).
Indian Pharma Network (IPN) can source Yupelri from its authorized distribution network and facilitate supply to patients, doctors, and hospitals under applicable legal provisions.
For Yupelri cost in India and availability, contact IPN at Phone: +91-9310090915 or email info@indianpharmanetwork.in.
Yupelri is used for the maintenance treatment of COPD.
Yupelri is developed by Theravance Biopharma and marketed by Viatris.
Via nebulizer, once daily, using a standard jet nebulizer.
Cost depends on monthly quantity and sourcing logistics — share your prescription with IPN for a quote.
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.
